Levetiracetam Al

Levetiracetam, the active ingredient in Levetiracetam Al, is an antiepileptic presented as an oral tablet for oral administration. It is indicated for the treatment of partial‑onset, primary generalized and secondary generalized seizures in individuals diagnosed with epilepsy, helping to reduce seizure frequency and improve neurological stability.

GNH USA supplies Levetiracetam Al as a licensed, GDP‑compliant international pharmaceutical product, sourced from the EU market and distributed to hospitals, pharmacies and clinics worldwide under strict quality standards. The company adheres to Good Distribution Practice and provides regulatory documentation to support import and clinical use.

Levetiracetam is an antiepileptic drug that acts on neuronal hyper‑excitability to control seizure activity.

Partial seizures: reduces frequency and severity of focal onset seizures. Generalized seizures: controls primary and secondary generalized tonic‑clonic seizures. Epilepsy: provides overall seizure management as part of a long‑term therapeutic regimen.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling of tiredness or reduced energy. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate cranial pain. - Irritability: mood changes or agitation. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: rare but serious skin disorder. - Blood dyscrasias: abnormal blood counts. - Suicidal ideation: thoughts of self‑harm. - Severe depression: marked mood disturbance. - Rhabdomyolysis: muscle breakdown leading to kidney injury.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

Renal function: adjust dose in patients with impaired renal clearance. Mood changes: monitor for depression, anxiety, or suicidal thoughts. Concomitant CNS depressants: use caution as additive sedation may occur. Pregnancy: evaluate risk‑benefit; limited data available. Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Levetiracetam can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: may decrease levetiracetam plasma levels. - Phenobarbital: may reduce levetiracetam exposure. - Phenytoin: may lower levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression. - Sedative antihistamines: may increase drowsiness. - Other antiepileptic drugs: may require dose adjustments.